Cilostazol Tested to Help Prevent Another Stroke or Heart Attack
Tests cilostazol against a placebo in adults over 40 after a stroke or mini-stroke.
Plain-language title generated from the registry record
Registry title: Cilostazol for Prevention of Recurrent Stroke Trial
Key facts
- Where
- Akron, Ann Arbor, Atlanta, Baltimore, Birmingham, Boston, Brooklyn, Carbondale, Chandler, Charleston, Charlottesville, Cincinnati, Columbia, Durham, Erie, Flint, Fontana, Grand Junction, Iowa City, Jacksonville, Kansas City, La Jolla, Los Angeles, Madison, Memphis, Minneapolis, Mobile, Morgantown, Murray, New Haven, New York, Oklahoma City, Philadelphia, Pomona, Portland, Richmond, Saint Paul, Salt Lake City, San Antonio, Seattle, St Louis, Stanford, Wilmington, and Winston-Salem, United StatesSee the 52 sites
- Phase
- Phase 3
Where in United States
- Cleveland Clinic Akron GeneralAkron, United StatesNo longer taking part
- University of Michigan University HospitalAnn Arbor, United StatesNo longer taking part
- Emory University HospitalAtlanta, United StatesNo longer taking part
- Grady Memorial HospitalAtlanta, United StatesNo longer taking part
- University of Maryland Medical CenterBaltimore, United StatesNo longer taking part
- University of Alabama Hospital - BirminghamBirmingham, United StatesNo longer taking part
- Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
- Boston Medical CenterBoston, United StatesNo longer taking part
- Kings County Hospital CenterBrooklyn, United StatesNo longer taking part
- NYU Langone Hospital - BrooklynBrooklyn, United StatesNo longer taking part
- Memorial Hospital of CarbondaleCarbondale, United StatesNo longer taking part
- Chandler Regional Medical CenterChandler, United StatesNo longer taking part
- Medical University of South Carolina- University HospitalCharleston, United StatesNo longer taking part
- UVA Medical CenterCharlottesville, United StatesNo longer taking part
- University of CinncinatiCincinnati, United StatesNo longer taking part
- Prisma Health Richland HospitalColumbia, United StatesNo longer taking part
- Duke University HospitalDurham, United StatesNo longer taking part
- UPMC HamotErie, United StatesNo longer taking part
- McLaren-FlintFlint, United StatesNo longer taking part
- Kaiser Permanente Fontana Medical CenterFontana, United StatesNo longer taking part
- Intermountain Health - St. Mary's Medical CenterGrand Junction, United StatesNo longer taking part
- University of Iowa Medical CenterIowa City, United StatesNo longer taking part
- UF Health JacksonvilleJacksonville, United StatesNo longer taking part
- University of Kansas HospitalKansas City, United StatesNo longer taking part
- UCSD Health La JollaLa Jolla, United StatesNo longer taking part
- Cedars-Sinai Medical CenterLos Angeles, United StatesNo longer taking part
- Kaiser Permanente Los Angeles Medical CenterLos Angeles, United StatesNo longer taking part
- University of Wisconsin - University HospitalMadison, United StatesNo longer taking part
- Methodist University HospitalMemphis, United StatesNo longer taking part
- Abbott-Northwestern HospitalMinneapolis, United StatesNo longer taking part
- M Health Fairview University of Minnesota Medical CenterMinneapolis, United StatesNo longer taking part
- University of South Alabama University HospitalMobile, United StatesNo longer taking part
- J.W. Ruby Memorial HospitalMorgantown, United StatesNo longer taking part
- Intermountain Medical CenterMurray, United StatesNo longer taking part
- Yale New Haven HospitalNew Haven, United StatesNo longer taking part
- NYP/Weill Cornell Medical CenterNew York, United StatesNo longer taking part
- Oklahoma University Medical CenterOklahoma City, United StatesNo longer taking part
- Hospital of the University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
- Temple University HospitalPhiladelphia, United StatesNo longer taking part
- Casa Colina HospitalPomona, United StatesNo longer taking part
- Oregon Health & Science University HospitalPortland, United StatesNo longer taking part
- Providence St. Vincent Medical CenterPortland, United StatesNo longer taking part
- Bon Secours St. Mary's HospitalRichmond, United StatesNo longer taking part
- Regions HospitalSaint Paul, United StatesNo longer taking part
- University of Utah HealthcareSalt Lake City, United StatesNo longer taking part
- University of Texas Health Science Center San AntonioSan Antonio, United StatesNo longer taking part
- Harborview Medical CenterSeattle, United StatesNo longer taking part
- Barnes-Jewish HospitalSt Louis, United StatesNo longer taking part
- SSM Health St. Louis University HospitalSt Louis, United StatesNo longer taking part
- Stanford UniversityStanford, United StatesNo longer taking part
- New Hanover Regional Medical CenterWilmington, United StatesNo longer taking part
- Wake Forest Baptist Medical CenterWinston-Salem, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT07174414
- Record updated
- 26 October 2026
- Original description
The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months.Read full original descriptionShow less
Cilostazol for Prevention of Recurrent Stroke Trial
The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months.
To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it.
Participants will:
* Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. * Not know which one they are taking, and neither will the study team, which keeps the results fair. * Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding.
Inclusion: ≥40 years; Ischemic stroke or high-risk TIA (ABCD2 score ≥6); Can be randomized within 180 days after ischemic stroke or high-risk TIA; Treatment with single or dual antithrombotic therapy with aspirin, clopidogrel and/or ticagrelor per international and/or national guidelines; Two or more of the following risk factors: age 65 years or older, hypertension, diabetes mellitus, history of ischemic stroke other than the qualifying event for this trial, currently smoking, peripheral arterial disease, coronary artery disease including prior MI, aortic atherosclerotic plaque ≥4 mm, ≥50% stenosis or occlusion of a major intracranial artery (ICA, M1, M2, A1, P1, vertebral, or basilar) or extracranial artery (ICA or vertebral); In the opinion of the site investigator, patient is medically stable, capable of participating in the trial, and willing and able to attend follow-up; Able to receive study drug by mail and able to begin taking study drug promptly after receipt; Provision of signed and dated informed consent form by patient or legally authorized representative.
Exclusion: Use of prohibited medication (as specified in the MOP); Confirmed diagnosis of heart failure with current or prior symptoms or signs (e.g. paroxysmal nocturnal dyspnea, reduced exercise tolerance, ankle swelling, elevated jugular venous pressure); Atrial fibrillation, mechanical heart valve, or left ventricular assist device; Planned cardiac surgery, percutaneous coronary intervention, carotid endarterectomy or stenting (patients are eligible post-procedure); History of symptomatic non-traumatic intracerebral hemorrhage within last 2 years; Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C); Hypersensitivity to cilostazol or any component of the formulation (e.g. anaphylaxis, angioedema); Participants who are incarcerated, including prisoners or participants compulsorily detained for treatment of psychiatric disease; Known thrombocytopenia (platelet count ≤100,000 per microliter (µL)); Modified Rankin Scale 5; Pregnant, breast-feeding, or of child-bearing potential but not on birth control; Currently enrolled in an investigational intervention study; Life expectancy less than 6 months; Participant does not allow contacting of their surrogate (e.g. family member or friend) or health care practitioner to obtain health information should participant become unwilling or unable to follow the study schedule.